These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 19373249)

  • 1. Assessing the potential of glucokinase activators in diabetes therapy.
    Matschinsky FM
    Nat Rev Drug Discov; 2009 May; 8(5):399-416. PubMed ID: 19373249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in glucokinase activators for the treatment of type 2 diabetes.
    Pal M
    Drug Discov Today; 2009 Aug; 14(15-16):784-92. PubMed ID: 19520181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
    Xu J; Lin S; Myers RW; Addona G; Berger JP; Campbell B; Chen HS; Chen Z; Eiermann GJ; Elowe NH; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; Malkani S; McMasters DR; Mitra K; Pachanski MJ; Tong X; Trujillo ME; Xu L; Zhang B; Zhang F; Zhang R; Parmee ER
    Bioorg Med Chem Lett; 2017 May; 27(9):2069-2073. PubMed ID: 28284804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.
    Matschinsky FM; Zelent B; Doliba NM; Kaestner KH; Vanderkooi JM; Grimsby J; Berthel SJ; Sarabu R
    Handb Exp Pharmacol; 2011; (203):357-401. PubMed ID: 21484579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes.
    Pal M
    Curr Med Chem; 2009; 16(29):3858-74. PubMed ID: 19747136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2.
    Li W; Zhang X; Sun Y; Liu Z
    Pharmazie; 2020 Jun; 75(6):230-235. PubMed ID: 32539915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
    Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
    Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
    Baker DJ; Wilkinson GP; Atkinson AM; Jones HB; Coghlan M; Charles AD; Leighton B
    Br J Pharmacol; 2014 Apr; 171(7):1642-54. PubMed ID: 24772484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Updates on Glucokinase Activators and Glucokinase Regulatory Protein Disrupters for the Treatment of Type 2 Diabetes Mellitus.
    Kaushik A; Kaushik M
    Curr Diabetes Rev; 2019; 15(3):205-212. PubMed ID: 30039763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.
    Grewal AS; Sekhon BS; Lather V
    Mini Rev Med Chem; 2014; 14(7):585-602. PubMed ID: 25052034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel glucokinase activators: a patent review (2008 - 2010).
    Sarabu R; Berthel SJ; Kester RF; Tilley JW
    Expert Opin Ther Pat; 2011 Jan; 21(1):13-33. PubMed ID: 21155690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucokinase activators for the potential treatment of type 2 diabetes.
    Grimsby J; Berthel SJ; Sarabu R
    Curr Top Med Chem; 2008; 8(17):1524-32. PubMed ID: 19075763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection.
    Lei L; Liu S; Li Y; Song H; He L; Liu Q; Sun S; Li Y; Feng Z; Shen Z
    Eur J Pharmacol; 2018 May; 826():17-23. PubMed ID: 29477658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus.
    Park K
    Arch Pharm Res; 2012 Dec; 35(12):2029-33. PubMed ID: 23263798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting glucokinase activation for the treatment of type 2 diabetes--a status review.
    Sarabu R; Grimsby J
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):631-7. PubMed ID: 16159025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric activators of glucokinase: potential role in diabetes therapy.
    Grimsby J; Sarabu R; Corbett WL; Haynes NE; Bizzarro FT; Coffey JW; Guertin KR; Hilliard DW; Kester RF; Mahaney PE; Marcus L; Qi L; Spence CL; Tengi J; Magnuson MA; Chu CA; Dvorozniak MT; Matschinsky FM; Grippo JF
    Science; 2003 Jul; 301(5631):370-3. PubMed ID: 12869762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?
    Matschinsky FM
    Trends Pharmacol Sci; 2013 Feb; 34(2):90-9. PubMed ID: 23305809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethnopharmacological perspectives of glucokinase activators in the treatment of diabetes mellitus.
    Sharma S; Wadhwa K; Choudhary M; Budhwar V
    Nat Prod Res; 2022 Jun; 36(11):2962-2976. PubMed ID: 34044681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A report of 2 new cases of MODY2 and review of the literature: implications in the search for type 2 diabetes drugs.
    Shammas C; Neocleous V; Phelan MM; Lian LY; Skordis N; Phylactou LA
    Metabolism; 2013 Nov; 62(11):1535-42. PubMed ID: 23890519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repair of diverse diabetic defects of β-cells in man and mouse by pharmacological glucokinase activation.
    Doliba NM; Fenner D; Zelent B; Bass J; Sarabu R; Matschinsky FM
    Diabetes Obes Metab; 2012 Oct; 14 Suppl 3(0 3):109-19. PubMed ID: 22928571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.